StemCell Institute Inc. (7096.T)
JPY 1329.0
(-0.3%)
JPY 1329.0
(-0.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 534.35 Million JPY | 20.38% |
| 2022 | 383.88 Million JPY | 36.97% |
| 2021 | 309.46 Million JPY | 156.58% |
| 2020 | 119.66 Million JPY | 12162.2% |
| 2019 | -1 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 153 Million JPY | 165.97% |
| 2023 Q2 | 126.68 Million JPY | 96.29% |
| 2023 Q4 | 57.53 Million JPY | -59.18% |
| 2023 Q3 | 140.94 Million JPY | 11.25% |
| 2023 FY | - JPY | 20.38% |
| 2023 Q1 | 64.54 Million JPY | 270.03% |
| 2022 Q3 | 124.71 Million JPY | 7.95% |
| 2022 FY | - JPY | 36.97% |
| 2022 Q4 | 17.44 Million JPY | -86.01% |
| 2022 Q2 | 115.53 Million JPY | 0.0% |
| 2021 FY | - JPY | 156.58% |
| 2020 FY | - JPY | 12162.2% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 44.228% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 209.469% |
| GNI Group Ltd. | 14.48 Billion JPY | 96.312% |
| Linical Co., Ltd. | 1.24 Billion JPY | 57.157% |
| Trans Genic Inc. | 240.95 Million JPY | -121.768% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 139.411% |
| Soiken Holdings Inc. | -583.2 Million JPY | 191.624% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 188.603% |
| AnGes, Inc. | -8.86 Billion JPY | 106.031% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 141.568% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 107.222% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | -317.115% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 161.918% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 148.943% |
| CanBas Co., Ltd. | 53.65 Million JPY | -895.981% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 168.896% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 577.951% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 144.098% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 138.698% |
| PeptiDream Inc. | 7.37 Billion JPY | 92.756% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 127.691% |
| Ribomic Inc. | -1.01 Billion JPY | 152.774% |
| SanBio Company Limited | -4.52 Billion JPY | 111.809% |
| Healios K.K. | -3 Billion JPY | 117.77% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 145.836% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 138.358% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 138.114% |
| StemRIM | -2.03 Billion JPY | 126.297% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 59.098% |
| FunPep Company Limited | -952 Million JPY | 156.13% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 160.123% |
| Stella Pharma Corporation | -723.85 Million JPY | 173.821% |
| TMS Co., Ltd. | -937 Million JPY | 157.028% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 168.914% |
| Cuorips Inc. | -518 Million JPY | 203.157% |
| K Pharma,Inc. | 366.05 Million JPY | -45.975% |
| Takara Bio Inc. | 8.02 Billion JPY | 93.341% |
| ReproCELL Incorporated | 8.24 Million JPY | -6380.946% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | -507.649% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | -118.269% |
| CellSeed Inc. | -836.51 Million JPY | 163.879% |